🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: Endocrine therapy + Abemaciclib

Found 73 matching trials

Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer

PHASE3

The purpose of this study is to evaluate the safety and efficacy of the stu...

Status

Active Not Recruiting

Location

University of Alabama Birmingham

Start Date

2017-07-12

Trial ID

NCT03155997

Treatments Being Tested

Abemaciclib Standard Adjuvant Endocrine Therapy

Abemaciclib in Combination With Endocrine Therapy as First Line Therapy in Metastatic Breast Cancer Patients

N/A

Breast cancer is one of the most common cancers in women. 20-30 % of all br...

Status

Completed

Location

Klinikum rechts der Isar der TU München, Klinik und Poliklinik für Frauenheilkunde

Start Date

2020-12-22

Trial ID

NCT04681768

Treatments Being Tested

Abemaciclib

A Non-interventional Study for Kisqali (Ribociclib) in Combination With an Aromatase Inhibitor for Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer at High Risk of Recurrence

N/A

This non-interventional observational study evaluates the real-world effect...

Status

Recruiting

Location

Novartis Investigative Site

Start Date

2025-02-20

Trial ID

NCT06830720

Treatments Being Tested

ribociclib + AI ± LHRH abemaciclib + ET ± LHRH ET mono ± LHRH

Discontinuation of CDK4/6 Inhibitors in Patients With Metastatic HR Positive, HER2 Negative Breast Cancer

PHASE2

This is a low-intervention, randomized, non-comparative, open-label, multic...

Status

Recruiting

Location

Charité Berlin

Start Date

2024-01-17

Trial ID

NCT06207734

Treatments Being Tested

Continuation of CDK4/6 inhibitor Palbociclib Discontinuation of CDK4/6 inhibitor Palbociclib Continuation of CDK4/6 inhibitor -Palbociclib Discontinuation of CDK4/6 inhibitor -Palbociclib Continuation of CDK4/6 inhibitor Abemaciclib Discontinuation of CDK4/6 inhibitor Abemaciclib

Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)

PHASE3

The study is intended to show superiority of AZD9833 in combination with CD...

Status

Active Not Recruiting

Location

Research Site

Start Date

2021-06-30

Trial ID

NCT04964934

Treatments Being Tested

AZD9833 AZD9833 Placebo Anastrozole Anastrozole placebo Letrozole Letrozole placebo Palbociclib Abemaciclib Luteinizing hormone-releasing hormone (LHRH) agonist Ribociclib

Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype

PHASE2

This trial studies a type of advanced breast cancer defined as hormone rece...

Status

Recruiting

Location

Medizinische Universität Graz

Start Date

2025-06-30

Trial ID

NCT06486883

Treatments Being Tested

Trastuzumab deruxtecan (T-DXd, DS-8201a)CDK4/6i plus ET

A Randomised Trial Comparing Trastuzumab Deruxtecan to CDK4/6 Inhibitors in Non-luminal A, ER-positive/HER2-low Metastatic Breast Cancer

PHASE3

The objective of this trial, DBCG R25, will be to evaluate the effect of tr...

Status

Withdrawn

Location

Multiple Locations

Start Date

2026-01-01

Trial ID

NCT06585969

Treatments Being Tested

Trastuzumab deruxtecan (T-DXd)Ribociclib with ET Abemaciclib with ET

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

PHASE2

The majority of patients (pts) with breast cancer have hormone receptor pos...

Status

Active Not Recruiting

Location

University of Miami

Start Date

2023-06-12

Trial ID

NCT05826964

Treatments Being Tested

AI+CDK4/6i SERD+CDK4/6i mTOR inhibitor + AI mTOR inhibitor + SERD mTOR inhibitor + Selective estrogen receptor modulator PI3K inhibitor + SERD PI3K inhibitor + AI Chemotherapy Oral SERD PARPi AKT inhibitor Step 3 Arm 2

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

PHASE3

The purpose of the study is to assess the efficacy and safety of the additi...

Status

Recruiting

Location

Alaska Oncology and Hematology

Start Date

2025-12-22

Trial ID

NCT07174336

Treatments Being Tested

LY4064809 Placebo Ribociclib Palbociclib Abemaciclib Anastrozole Letrozole Exemestane Fulvestrant

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

PHASE1

Study STX-478-101 (LY4064809) is a multipart, open-label, phase 1/2 study e...

Status

Recruiting

Location

Ellison Clinic at Saint John's

Start Date

2023-04-17

Trial ID

NCT05768139

Treatments Being Tested

STX-478 Fulvestrant Ribociclib Palbociclib Letrozole Anastrozole Exemestane Tamoxifen Abemaciclib Imlunestrant Metformin

Previous Next